BE739974A - - Google Patents

Info

Publication number
BE739974A
BE739974A BE739974DA BE739974A BE 739974 A BE739974 A BE 739974A BE 739974D A BE739974D A BE 739974DA BE 739974 A BE739974 A BE 739974A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE739974A publication Critical patent/BE739974A/xx

Links

Classifications

    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27FURNACES; KILNS; OVENS; RETORTS
    • F27DDETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D11/00Arrangement of elements for electric heating in or on furnaces
    • F27D11/08Heating by electric discharge, e.g. arc discharge
    • CCHEMISTRY; METALLURGY
    • C21METALLURGY OF IRON
    • C21CPROCESSING OF PIG-IRON, e.g. REFINING, MANUFACTURE OF WROUGHT-IRON OR STEEL; TREATMENT IN MOLTEN STATE OF FERROUS ALLOYS
    • C21C5/00Manufacture of carbon-steel, e.g. plain mild steel, medium carbon steel or cast steel or stainless steel
    • C21C5/52Manufacture of steel in electric furnaces
    • C21C5/5252Manufacture of steel in electric furnaces in an electrically heated multi-chamber furnace, a combination of electric furnaces or an electric furnace arranged for associated working with a non electric furnace
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27FURNACES; KILNS; OVENS; RETORTS
    • F27DDETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D11/00Arrangement of elements for electric heating in or on furnaces
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27FURNACES; KILNS; OVENS; RETORTS
    • F27DDETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D3/00Charging; Discharging; Manipulation of charge
    • F27D3/18Charging particulate material using a fluid carrier

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Organic Chemistry (AREA)
  • Vertical, Hearth, Or Arc Furnaces (AREA)
  • Furnace Details (AREA)
  • Discharge Heating (AREA)
BE739974D 1968-10-17 1969-10-08 BE739974A (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR170197 1968-10-17

Publications (1)

Publication Number Publication Date
BE739974A true BE739974A (cg-RX-API-DMAC10.html) 1970-03-16

Family

ID=8655735

Family Applications (1)

Application Number Title Priority Date Filing Date
BE739974D BE739974A (cg-RX-API-DMAC10.html) 1968-10-17 1969-10-08

Country Status (10)

Country Link
US (1) US3610795A (cg-RX-API-DMAC10.html)
JP (1) JPS4829422B1 (cg-RX-API-DMAC10.html)
BE (1) BE739974A (cg-RX-API-DMAC10.html)
BR (1) BR6913348D0 (cg-RX-API-DMAC10.html)
DE (1) DE1952407B2 (cg-RX-API-DMAC10.html)
ES (1) ES372628A1 (cg-RX-API-DMAC10.html)
FR (1) FR1601438A (cg-RX-API-DMAC10.html)
GB (1) GB1252310A (cg-RX-API-DMAC10.html)
LU (1) LU59646A1 (cg-RX-API-DMAC10.html)
SE (1) SE364311B (cg-RX-API-DMAC10.html)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891427A (en) * 1972-10-12 1975-06-24 Lectromelt Corp Method for melting prereduced ore and scrap
SE378735B (cg-RX-API-DMAC10.html) * 1972-11-17 1975-09-08 Asea Ab
FR2220584B1 (cg-RX-API-DMAC10.html) * 1973-03-05 1976-05-21 Siderurgie Fse Inst Rech
US3939297A (en) * 1973-12-07 1976-02-17 Chase Brass & Copper Co., Incorporated Stoker feed system
SE7503782L (sv) * 1975-04-02 1976-10-03 Asea Ab Sett och anordning for smeltreduktion av finkornigt jernoxidhaltigt material
DE2632707C3 (de) * 1976-07-21 1983-04-07 Ernst Dipl.-Ing. 4006 Erkrath Beiersdorf Beschickungsanlage an Elektro-Lichtbogenöfen zur Zugabe von Legierungsmitteln und Zuschlagstoffen
US4133967A (en) * 1977-06-24 1979-01-09 The United States Of America As Represented By The Secretary Of The Interior Two-stage electric arc - electroslag process and apparatus for continuous steelmaking
US4447906A (en) * 1981-02-02 1984-05-08 Lectromelt Corporation Arc furnace for producing aluminum
SE8303372L (sv) * 1983-06-14 1984-12-15 Asea Ab Ugnsanordning for smeltning av metaller eller metallegeringar
AT384669B (de) * 1986-03-17 1987-12-28 Voest Alpine Ag Anlage zur herstellung von stahl aus schrott
CA1311787C (en) * 1986-06-24 1992-12-22 Masahisa Tate Method of bottom blowing operation of a steel making electric furnace
FR2705767B1 (fr) * 1993-05-27 1995-07-21 Lorraine Laminage Procédé et installation de production d'acier liquide à partir de matières ferreuses riches en matières carbonées.
DE4339226A1 (de) * 1993-11-15 1995-05-18 Mannesmann Ag Verfahren und Vorrichtung zur Wertstoffgewinnung
LU88517A7 (fr) * 1993-12-15 1996-02-01 Wurth Paul Sa Dispositif de chargement d'un four électrique
AT404841B (de) 1995-04-10 1999-03-25 Voest Alpine Ind Anlagen Anlage und verfahren zum herstellen von eisenschmelzen
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
ATE301273T1 (de) * 1999-05-18 2005-08-15 Danieli Technology Inc Elektrischer lichtbogenofen und verfahren zum kontinuierlichen chargieren
EP1702983A3 (en) 2000-04-13 2007-01-10 Medical University of South Carolina Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof
AU2001278875B2 (en) * 2000-07-06 2007-06-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydrobenzothiazole analogues as neuroprotective agents
US6642002B2 (en) 2000-07-17 2003-11-04 Vanderbilt University Method of diagnosing pulmonary hypertension
WO2002030465A2 (en) 2000-10-12 2002-04-18 University Of Rochester Compositions that inhibit proliferation of cancer cells
WO2002081710A1 (en) * 2001-04-06 2002-10-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Artificial chromosomes that can shuttle between bacteria, yeast, and mammalian cells
BR0213043A (pt) * 2001-10-01 2004-10-05 Univ Vanderbilt Métodos de tratar ou prevenir dusfunção contrátil miocárdica após infarto do miocárdio em um sujeito, de tratar ou prevenir cardiomiopatia dilatada em um sujeito e de incrementar contratilidade miocárdica em um sujeito, animal transgênico, e, método de identificar um composto que pode tratar doença estrutural do coração
WO2003029430A2 (en) * 2001-10-04 2003-04-10 The Government Of The United States Of America, As Tandem repeat markers
CA2475112A1 (en) 2002-02-06 2003-08-14 Vicor Technologies, Inc. Anti-infarction molecules
ATE503233T1 (de) 2002-06-14 2011-04-15 Us Gov Health & Human Serv Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind
WO2004013160A2 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
PT1569685E (pt) 2002-11-15 2012-11-02 Univ Colorado Regents Recetor do complemento 2 direcionado a moduladores do complemento
AU2003294462C1 (en) 2002-11-21 2011-06-30 University Of Utah Research Foundation Purinergic modulation of smell
AU2005207002B2 (en) 2004-01-21 2011-03-17 University Of Utah Research Foundation Mutant sodium channel Nav1.7 and methods related thereto
AU2005220874B2 (en) 2004-03-04 2010-12-23 Vanderbilt University Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling
WO2006016904A2 (en) * 2004-04-14 2006-02-16 Uab Research Foundation Activators of hexosamine biosynthesis as inhibitors of injury induced by ischemia or hemorrhagic shock
US20050244335A1 (en) * 2004-05-03 2005-11-03 Rinehart John J Methods and compositions related to increasing antitumor activity of chemotherapeutic agents
JP2007537276A (ja) 2004-05-11 2007-12-20 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンティッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ, ナショナル イ グレリンを用いて炎症誘発性のサイトカイン発現を阻害する方法
WO2006083275A2 (en) 2004-05-21 2006-08-10 The Uab Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
WO2006055875A2 (en) * 2004-11-18 2006-05-26 University Of Rochester Methods and compositions related to esculentoside a
DK2377546T3 (en) 2004-12-21 2017-02-13 Musc Found For Res Dev Compositions and Methods to Promote Wound Healing and Tissue Regeneration
US9072716B2 (en) 2005-04-15 2015-07-07 The United States of America, as represented by the Secretary Department of Health by Human Servies Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells
EP2371843B1 (en) 2005-05-19 2014-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Functional epitopes of streptococcus pneumoniae psaA antigen and uses thereof
US8859585B2 (en) 2005-05-25 2014-10-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Scopolamine for the treatment of depression and anxiety
DK2468847T3 (en) 2005-06-07 2017-06-06 Dsm Nutritional Products Ag EUCARYOTIC MICRO-ORGANISMS FOR THE PREPARATION OF LIPIDS AND ANTIOXIDANTS
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2392646A1 (en) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
WO2007076537A2 (en) 2005-12-29 2007-07-05 The Regents Of The University Of California Methods and compositions related to mutant kunitz domain i of tfpi-2
EP1978987B1 (en) 2006-01-05 2014-12-31 University of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
WO2007092447A2 (en) * 2006-02-06 2007-08-16 Burnham Institute For Medical Research Methods and compositions related to targeting tumors and wounds
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US9365622B2 (en) * 2006-03-01 2016-06-14 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CA2644338A1 (en) 2006-03-02 2007-09-07 The Uab Research Foundation Mycobacterial disease detection, treatment, and drug discovery
CN101594867B (zh) 2006-07-10 2016-08-10 辛纳普辛制药有限公司 与火蚁毒素相关的组合物,以及它们在制备治疗神经系统障碍和提高认知和体能药物中的用途
CA2659574C (en) 2006-08-02 2017-04-25 The Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
CA2664189C (en) 2006-09-21 2017-11-21 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic dystrophy
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
BRPI0720038A2 (pt) 2006-12-11 2013-12-24 Univ Utah Res Found Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor
US20120030779A1 (en) 2007-01-18 2012-02-02 University Of Utah Research Foundtion Compositions and methods for detecting, treating, or preventing reductive stress
EP2117576B1 (en) 2007-02-08 2014-04-16 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
EP2139319A4 (en) 2007-03-22 2011-02-23 Univ Yale METHOD AND COMPOSITIONS FOR RIBOSWITCHES CONTROLLING THE ALTERNATIVE SPLICE
CA2685962A1 (en) 2007-05-08 2009-02-05 Burnham Institute For Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
EP2155894A4 (en) 2007-05-09 2010-08-18 Burnham Inst Medical Research HOST PROTEINAS AS A TARGET FOR A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL DISEASES
CA2688009C (en) 2007-05-23 2019-04-02 David E. Briles Detoxified pneumococcal neuraminidase and uses thereof
EP2426219A1 (en) 2007-05-29 2012-03-07 Yale University Riboswitches and methods and compositions for use of and with riboswitches
DK2166845T3 (en) 2007-06-21 2016-02-01 Musc Found For Res Dev ALFA-connexin C-terminal (ACT) peptides FOR THE TREATMENT OF AGE-related macular degeneration
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
US20110081317A1 (en) * 2007-08-08 2011-04-07 University Of Rochester Enhancing Gene Transfer
EP2190466A4 (en) * 2007-08-10 2011-12-21 Burnham Inst Medical Research Tissue-specific alkaline phosphatase (TNAP) activators and their use
CA2706317C (en) 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
WO2009137686A1 (en) 2008-05-08 2009-11-12 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
AU2009281732A1 (en) * 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
EP2370080A1 (en) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
EP2430161A1 (en) 2009-05-15 2012-03-21 Yale University Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
US20120149663A1 (en) 2009-08-18 2012-06-14 Georgetown University Boronic acid compositions and methods related to cancer
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US20120321647A1 (en) 2010-01-12 2012-12-20 Yale University Structured rna motifs and compounds and methods for their use
WO2011112670A2 (en) 2010-03-09 2011-09-15 Board Of Regents, University Of Texas System Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
US20110262347A1 (en) 2010-04-08 2011-10-27 The Salk Institute For Biological Studies Methods and compositions for enhanced delivery of compounds
WO2012021554A1 (en) 2010-08-09 2012-02-16 Yale University Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
CA2858811A1 (en) 2010-12-15 2012-06-12 Neuroadjuvants, Inc. Neuropeptide analogs, compositions, and methods for treating pain
RU2013145892A (ru) 2011-03-15 2015-04-20 Юниверсити Оф Юта Рисерч Фаундейшн Способы диагностики и лечения сосудисто-ассоциированной макулопатии и ее симптомов
WO2012135385A1 (en) 2011-03-28 2012-10-04 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
WO2013036636A1 (en) 2011-09-06 2013-03-14 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
US9732144B2 (en) 2012-07-05 2017-08-15 Ohio State Innovation Foundation Infectious bursal disease (IBDV) vaccine compositions
WO2014141111A1 (en) 2013-03-14 2014-09-18 Pluristem Ltd. Methods for prevention and treatment of graft-versus-host disease
US9783576B2 (en) 2013-06-11 2017-10-10 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
PL3016512T3 (pl) 2013-07-05 2020-09-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rozpuszczalny CD33 do leczenia zespołów mielodysplastycznych (MDS)
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
WO2016049380A1 (en) 2014-09-24 2016-03-31 University Of Utah Research Foundation Ebolavirus pre-hairpin intermediate mimics and methods of use
US10376549B2 (en) 2015-01-20 2019-08-13 Adcure Biotechnologies, Llc. Detargeted adenovirus variants and related methods
MX2017010698A (es) 2015-02-20 2018-04-30 Univ Texas Metodos y composiciones para chlamydia atenuada como vacuna y vector.
WO2017040350A1 (en) 2015-08-28 2017-03-09 Navigen, Inc Compositions and methods related to inhibition of respiratory syncytial virus entry
CN109069577B (zh) 2016-01-07 2022-08-19 纳维根公司 Hiv进入的d-肽抑制剂以及使用方法
WO2017160587A1 (en) 2016-03-16 2017-09-21 Abeome Corporation Neutralizing monoclonal antibodies to il-25 and uses thereof
US10751340B2 (en) 2016-06-06 2020-08-25 University Of Central Florida Research Foundation, Inc. Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions
WO2018023114A1 (en) 2016-07-29 2018-02-01 Ohio State Innovation Foundation Expression of pten-long with ocolytic viruses
DK3523416T3 (da) 2016-10-05 2025-03-03 Univ Central Florida Res Found Inc Fremgangsmåder og sammensætninger relateret til nk-celle- og anti-pdl1-kræftbehandlinger
KR102811217B1 (ko) 2017-02-28 2025-05-22 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Nk 세포의 골수 호밍을 개선시키는 pm21 입자
EP3600343B1 (en) 2017-03-24 2022-11-23 Ohio State Innovation Foundation Novel recombinant adeno-associated viral vectors restricting off-target transduction in liver and uses thereof
CA3058393A1 (en) 2017-03-28 2018-10-04 Ohio State Innovation Foundation Human pd1 peptide vaccines and uses thereof
US20230140818A1 (en) 2017-04-27 2023-05-04 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
WO2018218151A1 (en) 2017-05-25 2018-11-29 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
WO2019067403A2 (en) 2017-09-26 2019-04-04 Sanford Burnham Prebys Medical Discovery Institute COMPOSITIONS AND METHODS FOR EVALUATION OF PAINFUL DEMYELINIZING AND NON-DEMYELING DISEASES
US12053523B2 (en) 2017-12-13 2024-08-06 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
WO2019195819A1 (en) 2018-04-06 2019-10-10 North Carolina State University Cell assembly-mediated delivery of checkpoint inhibitors for cancer immunotherapy
WO2019217448A1 (en) 2018-05-07 2019-11-14 Georgia State University Research Foundation, Inc. Compositions and methods related to rhamnus prinoides (gesho) extract for the inhibition of polymicrobial biofilm formation
SG11202011313UA (en) 2018-05-16 2020-12-30 Res Inst Nationwide Childrens Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
KR20210042268A (ko) 2018-05-30 2021-04-19 다이렉트 바이오로직스 엘엘씨 간엽 줄기 세포(msc) 제제를 포함하는 성장 인자 및 세포외 소포 냉동 또는 분말화 첨가제 및 사용 방법
CN112638427A (zh) 2018-06-29 2021-04-09 北卡罗莱纳州立大学 用于术后治疗的原位喷雾生物响应性免疫治疗凝胶
EP3847650A1 (en) 2018-09-06 2021-07-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
US11331269B2 (en) 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
EP4588483A3 (en) 2018-10-03 2025-09-24 University of Pittsburgh- Of the Commonwealth System of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
WO2020092057A1 (en) 2018-10-30 2020-05-07 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
WO2020093035A1 (en) 2018-11-02 2020-05-07 The Johns Hopkins University Adenoviral chimeric tdp-43 proteins
US20220136064A1 (en) 2019-02-09 2022-05-05 King Abdullah University Of Science And Technology Compositions and methods for cancer diagnosis and prognosis
BR112021025795A2 (pt) 2019-06-21 2022-02-01 H Lee Moffitt Cancer Center And Res Institute Inc A Florida Non Profit Corporation Terapia de combinação com bloqueio da semaforina-4d (sema4d) e terapia com dc1
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
US20220401482A1 (en) 2019-10-31 2022-12-22 Research Institute At Nationwide Children's Hospital Generation of cd38 knock-out primary and expanded human nk cells
JP2023521837A (ja) 2020-04-14 2023-05-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 大きな配列の汎コロナウイルスワクチン組成物
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
WO2022115474A1 (en) 2020-11-27 2022-06-02 General Nanotherapeutics Llc Methods and composition for treatment of immune-mediated diseases
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
KR102436232B1 (ko) * 2022-01-17 2022-08-25 주식회사 세명하이트 원통형 필터 제조방법 및 이에 따라 제조된 원통형 필터
US20250228940A1 (en) 2022-03-11 2025-07-17 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
US20250161360A1 (en) 2022-05-10 2025-05-22 Yale University Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
KR102751454B1 (ko) * 2022-06-03 2025-01-10 현대제철 주식회사 전기로
KR102736561B1 (ko) * 2022-06-03 2024-12-02 현대제철 주식회사 전기로
KR102777625B1 (ko) * 2022-07-29 2025-03-11 현대제철 주식회사 전기로
KR102829902B1 (ko) * 2022-07-29 2025-07-04 현대제철 주식회사 전기로
KR102793154B1 (ko) * 2022-08-26 2025-04-07 현대제철 주식회사 전기로
KR102752443B1 (ko) * 2022-08-26 2025-01-09 현대제철 주식회사 전기로
WO2024064824A2 (en) 2022-09-21 2024-03-28 Yale University Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
US20240158490A1 (en) 2022-11-11 2024-05-16 Jeff R. Peterson Gout flare prevention methods using il-1beta blockers
KR102799788B1 (ko) * 2022-11-29 2025-04-22 현대제철 주식회사 전기로용 저취교반장치 및 이를 포함하는 전기로
WO2024155821A1 (en) 2023-01-18 2024-07-25 Yale University Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
WO2024238656A1 (en) 2023-05-15 2024-11-21 Yale Univeristy Chimeric antigen receptor compositions, car-mast cells formed therefrom, and methods of use thereof
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers
WO2025158400A1 (en) 2024-01-24 2025-07-31 Yale University Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025264861A1 (en) 2024-06-18 2025-12-26 Yale University Compositions of bi-functional alpha helical peptides and methods thereof for treating tdp-43 proteinopathies
WO2026006542A2 (en) 2024-06-26 2026-01-02 Yale University Compositions and methods for crispr/cas9 based reactivation of human angelman syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US848422A (en) * 1905-06-23 1907-03-26 Frank Wynne Method of maintaining or increasing the fluidity of molten or semimolten materials by means of electricity.
US1339428A (en) * 1916-03-24 1920-05-11 Ludlum Electric Furnace Corp Method of operating an electric furnace

Also Published As

Publication number Publication date
BR6913348D0 (pt) 1973-01-02
DE1952407A1 (de) 1970-08-20
JPS4829422B1 (cg-RX-API-DMAC10.html) 1973-09-10
FR1601438A (cg-RX-API-DMAC10.html) 1970-08-24
LU59646A1 (cg-RX-API-DMAC10.html) 1970-01-12
ES372628A1 (es) 1971-11-01
US3610795A (en) 1971-10-05
SE364311B (cg-RX-API-DMAC10.html) 1974-02-18
GB1252310A (cg-RX-API-DMAC10.html) 1971-11-03
DE1952407B2 (de) 1971-03-11

Similar Documents

Publication Publication Date Title
FR1601438A (cg-RX-API-DMAC10.html)
AU1946070A (cg-RX-API-DMAC10.html)
AU2374870A (cg-RX-API-DMAC10.html)
AU6168869A (cg-RX-API-DMAC10.html)
AU6171569A (cg-RX-API-DMAC10.html)
AU416157B2 (cg-RX-API-DMAC10.html)
AU2581067A (cg-RX-API-DMAC10.html)
AU2952567A (cg-RX-API-DMAC10.html)
AU4811568A (cg-RX-API-DMAC10.html)
AU2580267A (cg-RX-API-DMAC10.html)
AU3789668A (cg-RX-API-DMAC10.html)
AU3224368A (cg-RX-API-DMAC10.html)
AR203075Q (cg-RX-API-DMAC10.html)
BE709484A (cg-RX-API-DMAC10.html)
BE709319A (cg-RX-API-DMAC10.html)
BE727215A (cg-RX-API-DMAC10.html)
BE726780A (cg-RX-API-DMAC10.html)
BE726634A (cg-RX-API-DMAC10.html)
BE726322A (cg-RX-API-DMAC10.html)
BE726210A (cg-RX-API-DMAC10.html)
BE726007A (cg-RX-API-DMAC10.html)
BE725118A (cg-RX-API-DMAC10.html)
BE709496A (cg-RX-API-DMAC10.html)
BE727558A (cg-RX-API-DMAC10.html)
AU2889368A (cg-RX-API-DMAC10.html)